Premium
Algorithm for efficient PKHD1 mutation screening in autosomal recessive polycystic kidney disease (ARPKD)
Author(s) -
Bergmann Carsten,
Küpper Fabian,
Dornia Christian,
Schneider Frank,
Senderek Jan,
Zerres Klaus
Publication year - 2005
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.20145
Subject(s) - biology , autosomal recessive polycystic kidney disease , missense mutation , genetics , compound heterozygosity , locus (genetics) , allele , polycystic kidney disease , population , mutation , gene , medicine , kidney , environmental health
Autosomal recessive polycystic kidney disease (ARPKD) is an important cause of childhood renal‐ and liver‐related morbidity and mortality with variable disease expression. While most cases manifest peri‐/neonatally with a high mortality rate in the first month of life, others survive to adulthood. ARPKD is caused by mutations in the Polycystic Kidney and Hepatic Disease 1 ( PKHD1 ) gene on chromosome 6p12. PKHD1 is an exceptionally large gene (470 kb) with a longest open reading frame transcript of 67 exons predicted to encode a 4,074–amino acid (aa) (447 kDa) multidomain integral membrane protein (fibrocystin/polyductin) of unknown function. Recent DHPLC‐based mutational studies have reported detection rates of about 80% and a minimum of one PKHD1 mutation in more than 95% of families. Thus far, a total of 263 different PKHD1 mutations (639 mutated alleles) are included in the locus‐specific database (www.humgen.rwth‐aachen.de). Except for a few population‐specific founder alleles and the common c.107C>T (p.Thr36Met) missense change, PKHD1 is characterized by significant allelic diversity, making mutation screening time‐consuming and labor‐intensive. Mutations are distributed throughout the gene's coding sequence; however, they are not equally scattered. Thus, we aimed to set up an algorithm for efficient molecular genetic diagnostics in ARPKD. A total of 80% of known PKHD1 mutations can be identified if a subset of 27 out of 77 DHPLC fragments is screened. The current study provides an essential platform for PKHD1 mutation screening in a routine setting that will largely alleviate molecular genetic diagnostics in patients suspected to have ARPKD. Hum Mutat 25:225–231, 2005. © 2005 Wiley‐Liss, Inc.